Research ExplorerPublicationsExperimental in vitro, ex vivo and in vivo models in prostat...

Experimental in vitro, ex vivo and in vivo models in prostate cancer research

Standard

Experimental in vitro, ex vivo and in vivo models in prostate cancer research. / Sailer, Verena; von Amsberg, Gunhild; Duensing, Stefan; Kirfel, Jutta; Lieb, Verena; Metzger, Eric; Offermann, Anne; Pantel, Klaus; Schuele, Roland; Taubert, Helge; Wach, Sven; Perner, Sven; Werner, Stefan; Aigner, Achim.

In: NAT REV UROL, Vol. 20, No. 3, 03.2023, p. 158-178.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Sailer, V, von Amsberg, G, Duensing, S, Kirfel, J, Lieb, V, Metzger, E, Offermann, A, Pantel, K, Schuele, R, Taubert, H, Wach, S, Perner, S, Werner, S & Aigner, A 2023, 'Experimental in vitro, ex vivo and in vivo models in prostate cancer research', NAT REV UROL, vol. 20, no. 3, pp. 158-178. https://doi.org/10.1038/s41585-022-00677-z

APA

Sailer, V., von Amsberg, G., Duensing, S., Kirfel, J., Lieb, V., Metzger, E., Offermann, A., Pantel, K., Schuele, R., Taubert, H., Wach, S., Perner, S., Werner, S., & Aigner, A. (2023). Experimental in vitro, ex vivo and in vivo models in prostate cancer research. NAT REV UROL, 20(3), 158-178. https://doi.org/10.1038/s41585-022-00677-z

Vancouver

Sailer V, von Amsberg G, Duensing S, Kirfel J, Lieb V, Metzger E et al. Experimental in vitro, ex vivo and in vivo models in prostate cancer research. NAT REV UROL. 2023 Mar;20(3):158-178. https://doi.org/10.1038/s41585-022-00677-z

Bibtex

@article{4437c731b840416a80ff8b010a0cb78f,
title = "Experimental in vitro, ex vivo and in vivo models in prostate cancer research",
abstract = "Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual disease progression. Novel treatment approaches are urgently needed, but only a fraction of promising drug candidates from the laboratory will eventually reach clinical approval, highlighting the demand for critical assessment of current preclinical models. Such models include standard, genetically modified and patient-derived cell lines, spheroid and organoid culture models, scaffold and hydrogel cultures, tissue slices, tumour xenograft models, patient-derived xenograft and circulating tumour cell eXplant models as well as transgenic and knockout mouse models. These models need to account for inter-patient and intra-patient heterogeneity, the acquisition of primary or secondary resistance, the interaction of tumour cells with their microenvironment, which make crucial contributions to tumour progression and resistance, as well as the effects of the 3D tissue network on drug penetration, bioavailability and efficacy.",
author = "Verena Sailer and {von Amsberg}, Gunhild and Stefan Duensing and Jutta Kirfel and Verena Lieb and Eric Metzger and Anne Offermann and Klaus Pantel and Roland Schuele and Helge Taubert and Sven Wach and Sven Perner and Stefan Werner and Achim Aigner",
note = "{\textcopyright} 2022. Springer Nature Limited.",
year = "2023",
month = mar,
doi = "10.1038/s41585-022-00677-z",
language = "English",
volume = "20",
pages = "158--178",
journal = "NAT REV UROL",
issn = "1759-4812",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Experimental in vitro, ex vivo and in vivo models in prostate cancer research

AU - Sailer, Verena

AU - von Amsberg, Gunhild

AU - Duensing, Stefan

AU - Kirfel, Jutta

AU - Lieb, Verena

AU - Metzger, Eric

AU - Offermann, Anne

AU - Pantel, Klaus

AU - Schuele, Roland

AU - Taubert, Helge

AU - Wach, Sven

AU - Perner, Sven

AU - Werner, Stefan

AU - Aigner, Achim

N1 - © 2022. Springer Nature Limited.

PY - 2023/3

Y1 - 2023/3

N2 - Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual disease progression. Novel treatment approaches are urgently needed, but only a fraction of promising drug candidates from the laboratory will eventually reach clinical approval, highlighting the demand for critical assessment of current preclinical models. Such models include standard, genetically modified and patient-derived cell lines, spheroid and organoid culture models, scaffold and hydrogel cultures, tissue slices, tumour xenograft models, patient-derived xenograft and circulating tumour cell eXplant models as well as transgenic and knockout mouse models. These models need to account for inter-patient and intra-patient heterogeneity, the acquisition of primary or secondary resistance, the interaction of tumour cells with their microenvironment, which make crucial contributions to tumour progression and resistance, as well as the effects of the 3D tissue network on drug penetration, bioavailability and efficacy.

AB - Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual disease progression. Novel treatment approaches are urgently needed, but only a fraction of promising drug candidates from the laboratory will eventually reach clinical approval, highlighting the demand for critical assessment of current preclinical models. Such models include standard, genetically modified and patient-derived cell lines, spheroid and organoid culture models, scaffold and hydrogel cultures, tissue slices, tumour xenograft models, patient-derived xenograft and circulating tumour cell eXplant models as well as transgenic and knockout mouse models. These models need to account for inter-patient and intra-patient heterogeneity, the acquisition of primary or secondary resistance, the interaction of tumour cells with their microenvironment, which make crucial contributions to tumour progression and resistance, as well as the effects of the 3D tissue network on drug penetration, bioavailability and efficacy.

U2 - 10.1038/s41585-022-00677-z

DO - 10.1038/s41585-022-00677-z

M3 - SCORING: Review article

C2 - 36451039

VL - 20

SP - 158

EP - 178

JO - NAT REV UROL

JF - NAT REV UROL

SN - 1759-4812

IS - 3

ER -